Amarantus BioSciences, Inc. Appoints Adam J. Simon, Ph.D., to Board of Advisors  
4/2/2013 6:31:25 AM

Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, has appointed Adam J. Simon, Ph.D., to its Board of Advisors. Dr. Simon is a world expert in the field of Alzheimer’s disease biomarkers and has significant expertise in the development of in-vitro diagnostics.